text_1: Therapeutics receiving accelerated approval encounter a lower frequency of post-marketing safety events
text_2: Exposures Novel therapeutic characteristics known at the time of FDA approval, including drug class, therapeutic area, priority review, accelerated approval, orphan status, near–regulatory deadline approval, and regulatory review time.